seekingalpha.com
AtriCure, Inc. (ATRC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
AtriCure, Inc. (ATRC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
AtriCure, Inc.ATRCNASDAQ
LOADING
|||
Latest News
businesswire.com
AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2025, Provides Financial Outlook for 2026
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced preliminary financial results for the fourth quarter and full year 2025 and provided 2026 financial guidance. Preliminary, unaudited revenue for fourth quarter 2025 is expected to be $140.5 million, reflecting growth of approximately 13% over the fourth quar.
zacks.com
AtriCure, Inc. (ATRC) Soars to 52-Week High, Time to Cash Out?
AtriCure (ATRC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
defenseworld.net
AtriCure, Inc. (NASDAQ:ATRC) Receives Average Recommendation of “Moderate Buy” from Brokerages
AtriCure, Inc. (NASDAQ: ATRC - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the eleven ratings firms that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and ten have given a buy rating to the company. The average 1 year price objective
defenseworld.net
AtriCure, Inc. (NASDAQ:ATRC) Given Consensus Recommendation of “Moderate Buy” by Analysts
Shares of AtriCure, Inc. (NASDAQ: ATRC - Get Free Report) have been given an average rating of "Moderate Buy" by the eleven brokerages that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation and ten have issued a buy recommendation on the company. The average 1 year target
zacks.com
Has AtriCure (ATRC) Outpaced Other Medical Stocks This Year?
Here is how AtriCure (ATRC) and Ensign Group (ENSG) have performed compared to their sector so far this year.
zacks.com
AtriCure (ATRC) Is Up 6.32% in One Week: What You Should Know
Does AtriCure (ATRC) have what it takes to be a top stock pick for momentum investors? Let's find out.
businesswire.com
AtriCure to Participate in the J.P. Morgan 44th Annual Healthcare Conference
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming J.P. Morgan 44th Annual Healthcare Conference. AtriCure's management is scheduled to present on Wednesday, January 14, 2026, at 10:30 a.m. Pacific Standard Time. Interested parties may access a live aud.
zacks.com
ATRC Treats First Patients Using Novel Dual-Energy PFA-RFA Platform
AtriCure's first patients treated with its dual-energy PFA-RFA platform mark a key step as it moves toward a clinical trial next year.
businesswire.com
AtriCure Announces the First Patients Treated with Novel Dual Energy Platform
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced successful first-in-human treatments using its novel dual energy platform that integrates Pulsed Field Ablation (PFA) with Advanced Radiofrequency Ablation (Advanced RFA). The procedures were performed by Dr. Adrian Pick in collaboration with the site Princi.
zacks.com
Are Medical Stocks Lagging AtriCure (ATRC) This Year?
Here is how AtriCure (ATRC) and Boston Scientific (BSX) have performed compared to their sector so far this year.
fool.com
Is AtriCure Stock a Buy or Sell After a Director Dumped 10,000 Shares?
AtriCure Board of Directors member Sven Wehrwein sold 10,000 shares in the company on Nov. 24 and 25, 2025. The transaction was valued at nearly $377,000.
zacks.com
Wall Street Analysts Believe AtriCure (ATRC) Could Rally 36.3%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 36.3% in AtriCure (ATRC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
zacks.com
Is AtriCure (ATRC) Stock Outpacing Its Medical Peers This Year?
Here is how AtriCure (ATRC) and Cidara Therapeutics (CDTX) have performed compared to their sector so far this year.
businesswire.com
AtriCure to Participate in the Piper Sandler 37th Annual Healthcare Conference
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Piper Sandler 37th Annual Healthcare Conference. AtriCure's management is scheduled to participate in a fireside discussion on Tuesday, December 2, 2025, at 10:00 a.m. Eastern Standard Time. Interested.
defenseworld.net
8,681 Shares in AtriCure, Inc. $ATRC Purchased by Campbell & CO Investment Adviser LLC
Campbell and CO Investment Adviser LLC purchased a new stake in AtriCure, Inc. (NASDAQ: ATRC) in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 8,681 shares of the medical device company's stock, valued at approximately $284,000. Other hedge funds also recently made changes
seekingalpha.com
AtriCure, Inc. (ATRC) Presents at UBS Global Healthcare Conference 2025 Transcript
AtriCure, Inc. ( ATRC ) UBS Global Healthcare Conference 2025 November 10, 2025 2:00 PM EST Company Participants Angela Wirick - Chief Financial Officer Michael H. Carrel - CEO, President & Director Conference Call Participants Danielle Antalffy - UBS Investment Bank, Research Division Presentation Danielle Antalffy UBS Investment Bank, Research Division Well, good afternoon, everyone.
zacks.com
AtriCure (ATRC) Loses 13.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for AtriCure (ATRC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
zacks.com
Here's What Key Metrics Tell Us About AtriCure (ATRC) Q3 Earnings (Revised)
While the top- and bottom-line numbers for AtriCure (ATRC) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
zacks.com
Is AtriCure (ATRC) Outperforming Other Medical Stocks This Year?
Here is how AtriCure (ATRC) and Cabaletta Bio, Inc. (CABA) have performed compared to their sector so far this year.